Business Context and Reporting Period
Company: Exelixis, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Exelixis is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and other serious diseases. The company utilizes an integrated drug discovery platform to advance compounds through preclinical and clinical stages. As of the reporting date, the company had no approved pharmaceutical products and generated revenue primarily through collaboration agreements, license fees, and research funding.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Total Revenues | $76.0 million | $52.9 million |
| Net Loss | $(84.4) million | $(137.2) million |
| Research & Development Expenses | $141.1 million | $137.7 million |
| General & Administrative Expenses | $27.7 million | $20.9 million |
| Cash and Cash Equivalents | $96.5 million | $78.1 million |
| Total Cash, Marketable Securities & Investments | $210.5 million | $171.2 million |
| Working Capital | $101.6 million | $100.2 million |
| Long-Term Debt (excluding current portion) | $106.9 million | $136.4 million |
| Accumulated Deficit | $(603.8) million | $(519.4) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 44% to $76.0 million, driven by a $12.3 million increase in revenue from GlaxoSmithKline (GSK) due to milestone achievements and increased funding, and a $9.6 million increase from Genoptera due to the acceleration of upfront payments and termination fees.
- Net Loss Reduction: Net loss decreased significantly to $84.4 million from $137.2 million in 2004. This improvement was primarily due to a $52.8 million decrease in the net loss, partially offset by the consolidation of Symphony Evolution, Inc. (SEI) losses.
- Acquisition Impact: In 2004, the company recorded a $26.0 million charge for acquired in-process research and development (IPR&D) related to the X-Ceptor acquisition. No such charge was recorded in 2005.
- Collaboration Terminations: The Genoptera collaboration was terminated in 2005, resulting in a one-time revenue acceleration. The company will not receive further revenue from Genoptera after 2005.
Guidance, Outlook, and Risks
Outlook and Liquidity
Management anticipates that current cash, marketable securities, investments held by SEI, and committed financing will enable operations for at least the next 12 months. This estimate includes the scheduled repayment of a $30.0 million convertible promissory note to Protein Design Labs due in May 2006. The company expects to continue incurring net losses as it advances its clinical pipeline.
Key Risks and Contingencies
- Capital Requirements: The company requires substantial additional capital to fund clinical trials and operations. Failure to raise funds could force delays or elimination of programs.
- Financial Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with covenants in its loan agreement with GSK. As of Dec 31, 2005, the company was in compliance ($101.6M working capital; $210.5M cash/investments).
- SEI Repurchase Options: The company licensed three compounds (XL647, XL999, XL784) to Symphony Evolution, Inc. (SEI) for up to $80.0 million in funding. Exelixis retains options to reacquire these compounds. If GSK selects these compounds for further development, Exelixis must repurchase them from SEI, potentially requiring significant cash or equity issuance.
- Clinical Trial Uncertainty: Success depends on the safety and efficacy of product candidates in clinical trials. Failure in trials could prevent regulatory approval and commercialization.
- Accounting Changes: The company will adopt SFAS 123R in 2006, requiring the recognition of stock-based compensation expense, estimated to be between $15.0 million and $20.0 million for 2006.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $210.5 million cash position against the $30.0 million PDL note due in May 2006 and ongoing R&D burn rates.
- SEI Repurchase Liability: Assess the financial impact of potential repurchase obligations for XL647, XL999, and XL784 if GSK exercises its selection rights under the collaboration agreement.
- Clinical Milestones: Monitor the progress of the Phase 3 trial for XL119 (managed by Helsinn) and Phase 2 trials for XL999 and XL647, as these drive future milestone revenues.
- Stock-Based Compensation: Review the impact of the new SFAS 123R standard on 2006 earnings, as the company currently expenses minimal stock compensation under APB 25.
- Collaboration Dependencies: Evaluate the concentration risk with GlaxoSmithKline, which accounted for 37% of 2005 revenues.